EMH.V - Emerald Health Therapeutics, Inc.

TSXV - TSXV Delayed Price. Currency in CAD
1.7500
-0.0200 (-1.13%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.7700
Open1.7500
Bid1.7600 x 0
Ask1.7800 x 0
Day's Range1.7000 - 1.7800
52 Week Range1.6700 - 5.4000
Volume190,559
Avg. Volume431,366
Market Cap261.525M
Beta (3Y Monthly)2.28
PE Ratio (TTM)N/A
EPS (TTM)-0.1580
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.22
  • GlobeNewswire

    Emerald Health Therapeutics Forms Partnership With HelloMD to Continue Expanding its Medical Cannabis Patient Program

    OTCQX: EMHTF), a Canadian licenced producer of medicinal and recreational cannabis products, and HelloMD, a leading online cannabis healthcare company, have announced a partnership to further streamline and enhance Emerald’s patient onboarding experience. As part of this new partnership, Emerald has integrated HelloMD's industry-leading turnkey virtual services and patient onboarding solutions into its program for medical cannabis patients.

  • 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk
    InvestorPlace

    7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk

    [Editor's note: This story will be updated each week with new stocks and analysis. Please check back often for Mark's latest take on marijuana penny stocks.]There is no doubt that the cannabis industry is here to stay. In my opinion, legalization on a federal level in the United States will occur sooner than most analysts think. This will cause the industry to boom even more.This is because federal legalization means that recreational and medical marijuana companies will be able to engage in standard banking procedures and practices like other businesses. This exclusion from standard procedures has been an impediment to the growth of the industry. Many cannabis companies are literally forced to pay their taxes with cash.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMarijuana penny stocks are especially appealing to some people. Every investor has dreams of investing a couple thousand dollars into a penny stock company that will become the next Apple (NASDAQ:AAPL) or Facebook (NASDAQ:FB). Then they can head off into the sunset and live happily every after.However, you need to be very careful if you want to invest in this highly risky sector of the markets. Many of these companies will not survive. There is a reason why they are trading as penny stocks. But it is reasonable to assume that in an industry with as much potential as cannabis, there are some future millionaire makers out there. * 10 Stocks to Sell in Market-Cursed September These are not "buy" recommendations. I just want to share some insight into this part of the equity markets that may help you with your own investments. The Green Organic Dutchman (TGODF)The Green Organic Dutchman (OTCMKTS:TGODF) is a Canadian-based cannabis research and development company. Aurora Cannabis (NYSE:ACB) was a major shareholder of TGODF. However, last week the companies announced that Aurora has sold its 28.8 million shares at a price of $3 CAD to a syndicate of Canadian Banks. TGODF stock dropped over 10% on the news.The Green Organic Dutchman says this will ultimately be a good thing because it no longer has any revenue-sharing arrangements with Aurora. Does this mean ACB is negative on TGODF? Not necessarily. Aurora has many problems including huge losses and an excessive amount of goodwill. Selling its TGODF stock could just be a relatively easy way to raise some badly needed cash.This transaction could weigh on the stock in the short term. This is because this syndicate of Canadian Banks are likely to have to get out of their positions, so traders know that there will be sellers in the market. Pure Global Cannabis (PRCNF)Pure Global Cannabis (OTCMKTS:PRCNF) produces cannabis products for the medical and adult use markets. Products include dried flowers, cannabis oils, softgels, edibles and beverages.This company just announced what it considers to be an important milestone in its history. It has received approval from Health Canada for its most recent license. This will allow it to sell cannabis oil products. This will also help the company get approvals for phase two cultivation and extraction.PRCNF shareholders can't be too happy. Like many others in the industry, the stock has not done well. Since earlier this year it has dropped from 30 cents to current levels around 8 cents. It is too soon to know if this news will help to turn things around, but there doesn't seem to be any effect on the stock yet. I will be watching this one. Heritage Cannabis (HERTF)Heritage Cannabis (OTCMKTS:HERTF) is focused on becoming a vertically integrated cannabis provider. HERTF just passed the 30 cent level. This level was support in June. It was also a resistance level from May through October of 2018.Why would a former resistance level become a support level? It is because the people who sold it at the resistance level were feeling pretty good when it went lower. But then it rallied and went higher than that level. Now those sellers believe that they made the wrong decision. They tell themselves that they will buy it back if it drops once more. * 7 Stocks to Buy In a Flat Market Those who bought it at resistance were feeling good when it went higher and they are now looking at a profit. They tell themselves that if the stock drops back to that level they will buy more and add to their positions. Emerald Health Therapeutics (EMHTF)Emerald Health Therapeutics (OTCMKTS:EMHTF) grows and sells medical marijuana in Canada. It also develops natural health products. Emerald just announced that its 50%-owned joint venture Pure Sunfarms received an amendment to its license from Health Canada. This amendment will allow the joint venture to sell and distribute Pure Sunfarms-branded cannabis products. Pure Sunfarms has already established a distribution agreement with the British Columbia Liquor Distribution Branch.This comes after an announcement that Pure Sunfarms entered a supply agreement with the Ontario Cannabis Retail Corporation. Pure Sunfarms will begin shipping to Ontario and British Columbia in the coming weeks.In addition to this potentially bullish news, Emerald also recently disclosed second-quarter sales of $5.1 million. This was an increase of 94% versus the first quarter. Choom (CHOOF)Choom (OTCMKTS:CHOOF) cultivates and sells cannabis for medical purposes and related products. Needless to say, shareholders have not been happy. The price of CHOOF stock has lost about 50% of its value since March. However, there has been a series of seemingly positive developments. Maybe this will help the stock turn around.Choom has recently announced that it is opening seven new retail locations. These include stores in Alberta and British Columbia. In addition to these new stores, Choom has also made a series of acquisitions including Ninetails Cannabis -- a licensed cannabis retail store in Whitehorse, Yukon.It is too soon to know whether these announcements will turn the stock around, but Choom is a name worth paying attention to. Leafbuyer Technologies (LBUY)Leafbuyer Technologies (OTCMKTS:LBUY) operates an online platform that connects consumers with dispensaries. Shareholders of LBUY have been dealing with a harsh buzz. Having lost 90% of its value since March, the stock has basically crashed.Since the beginning of August there has been huge volume of trading. This could be a sign of capitulation and a signal that LBUY stock is about to turn around.Capitulation is when sellers throw in the towel. In other words, they just want to get out of the stock and put an end to their misery. They just want to sell it -- and they don't care about the price. * 7 Deeply Discounted Energy Stocks to Buy Ironically, this could be a bullish dynamic for the stock. This is because the sellers are about to leave the market. Due to the lack of sellers or supply that exists after this, buyers will have to pay much higher prices in order to complete their orders. This will cause the stock to rally. Helix TCS (HLIX)Helix TCS (OTCMKTS:HLIX) provides technology, compliance and security solutions to the cannabis industry. HLIX recently announced that it added a seasoned veteran to its leadership team. Garvis Toler, the former global head of capital markets at the New York Stock Exchange, is Helix TCS's new president of data services.The cannabis industry is full of incompetent management. Many of the entrepreneurs that founded successful companies do not have the skills required to manage their businesses as they grow and mature. The fact that Helix is bringing in someone with extensive experience could give it a competitive advantage over its rivals.In addition to this potentially positive development, the company also just announced second-quarter results. It highlighted that revenue was $3.9 million, which was up 108% from the same quarter last year, while gross margins were an impressive 49%.At the time of this writing Mark Putrino did not hold any positions in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 8 Worst Stocks to Buy Before the Trade Turmoil Cools Off * 7 'Strong Buy' Stocks to Beat Volatility * 7 Mega-Cap Tech Stocks on a Rebound Now The post 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk appeared first on InvestorPlace.

  • GlobeNewswire

    Emerald Health Therapeutics’ Joint Venture, Pure Sunfarms, Receives License Amendment to Supply Cannabis Products Directly to Provincial/Territorial Wholesalers and Authorized Private Retailers

    OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has received from Health Canada the amendment to its license permitting it to sell and distribute packaged, Pure Sunfarms-branded dried cannabis products directly to provincial/territorial wholesalers and authorized private retailers in accordance with provincial/territorial frameworks in Canada. Pure Sunfarms currently has supply agreements in place with the Ontario Cannabis Retail Corporation ( “OCRC”, operating as the Ontario Cannabis Store) and British Columbia Liquor Distribution Branch (“BCLDB”).

  • GlobeNewswire

    Emerald Health Therapeutics Announces Pure Sunfarms’ Cannabis Supply Agreement with British Columbia Liquor Distribution Branch

    OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms (PSF), has entered into a supply agreement with the British Columbia Liquor Distribution Branch (BCLDB) to supply Pure Sunfarms-branded cannabis products for the recreational market in the Province of British Columbia. Pure Sunfarms will begin shipping to the BCLDB and the Ontario Cannabis Retail Corporation (the “OCRC,” operating as the Ontario Cannabis Store) as soon as it receives its Health Canada license amendment permitting sales and distribution of packaged cannabis products directly to provincial/territorial wholesalers and authorized private retailers in accordance with the provincial/territorial framework in Canada.

  • Benzinga

    Emerald Health Therapeutics Discloses Q2 Sales Of $5.1M

    Emerald Health Therapeutics achieved positive adjusted EBITDA of $1.9 million, up by $5.4 million from the first quarter. During the second quarter, Emerald Health Therapeutics worked on improving the success of Pure Sunfarms, completing the licensing endeavors of its facilities, enabling the extraction of THC and CBD oil, and starting the distribution of new non-cannabis products that can inflect the endocannabinoid system to advance consumer’s health. The company also appointed Riaz Bandali as the new CEO.

  • GlobeNewswire

    Emerald Health Therapeutics Reports Second Quarter 2019 Financial Results; Sales Double Second Quarter in a Row

    Full versions of the Company’s unaudited condensed, interim consolidated financial statements and MD&A for such period can be found on SEDAR at www.sedar.com. “During the second quarter, we appointed Riaz Bandali as Chief Executive Officer, adding extensive senior operating experience to our team and in-depth insight in the life science industry.

  • GlobeNewswire

    Emerald Health Therapeutics to Present at Rodman & Renshaw 21st Annual Global Investment Conference

    VANCOUVER, British Columbia, Aug. 28, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that it will present a corporate overview.

  • GlobeNewswire

    Emerald Health Therapeutics Announces $25 Million Convertible Debenture Unit Financing

    OTCQX: EMHTF) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subject to certain customary conditions, to purchase 2,500 secured convertible debenture units (each, a “Convertible Debenture Unit”) of the Company at a price of $10,000 per Convertible Debenture Unit (the “Issue Price”) for gross proceeds of $25,000,000 (the “Offering”). Each Convertible Debenture Unit is comprised of one 5.0% secured convertible debenture of the Company in the principal amount of $10,000 (each, a "Convertible Debenture") and 5,000 common share purchases warrants of the Company (each, a "Warrant").

  • GlobeNewswire

    Emerald Health Therapeutics’ Pure Sunfarms JV Reaches Q2 Sales of $32 Million, 78% EBITDA Margin, $0.65/Gram All-in Production Cost, and Third Consecutive Quarter of Profitability

    OTCQX: EMHTF) has provided preliminary, unaudited financial results for the second quarter of 2019 for its BC-based 50%-owned joint venture, Pure Sunfarms (PSF). The Company will report its complete financial results for the second quarter ended June 30, 2019, after market close on Wednesday, August 28th, 2019, and host its second quarter 2019 financial results conference call on Thursday, August 29th, 2019 at 10:30 a.m. ET.

  • GlobeNewswire

    Emerald Health Therapeutics Outlines Production and Processing Advancements

    “With the first 1.1 million square foot (25 acre) greenhouse of our Pure Sunfarms joint venture now in full production and producing material net income and the second 1.1 million square foot greenhouse being converted for operation in 2020, we are now focused on finishing construction, licensing, and operational scaling of commercial cultivation and post-harvest processing in our other facilities and with third-party service providers, and have recently had multiple accomplishments to report,” said Riaz Bandali, Chief Executive Officer of Emerald.

  • GlobeNewswire

    Emerald Health Therapeutics Appoints Chief Executive Officer

    OTCQX: EMHTF) has appointed Riaz Bandali as Chief Executive Officer. Mr. Bandali has over 25 years of experience in life sciences, with expertise in global operations, strategy development, innovation cultivation, M&A, and investment management spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

  • GlobeNewswire

    Emerald Health Therapeutics’ New Organic Cannabis Operation Receives Cultivation License for Outdoor Grow Area

    OTCQX: EMHTF) has received its cultivation license from Health Canada for the 12-acre outdoor grow area at its new organic cannabis operation in Metro Vancouver, BC. The outdoor grow area is expected to be capable of producing approximately 10,000 kg of cannabis annually with multiple crops during a full growing season. With this license effective as of July 12, 2019, Emerald is positioned to deliver one harvest and a portion of the expected full production volume this year. The 12 acres (~500,000 square feet) of outdoor cultivation are part of an overall 20-acre site that includes 156,000 sq. ft. in two greenhouses.

  • GlobeNewswire

    Emerald Health Therapeutics’ Joint Venture Achieves Its Full Annualized Production Run-Rate

    OTCQX: EMHTF) 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has achieved its full production run-rate of 75,000 kilograms of dried cannabis at its 1.1 million square foot Delta 3 greenhouse in Delta, British Columbia. “Pure Sunfarms’ growing operation is setting the standard for large-scale low cost high quality cannabis production, which we believe serves as a strong indication of what the combined expertise of Emerald and Village Farms can accomplish,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald.

  • GlobeNewswire

    Emerald Health Therapeutics Expands Distribution of its SYNC 25 CBD Oil to Two More Canadian Provinces

    VANCOUVER, British Columbia, July 10, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has shipped 9,960 40-ml units of its SYNC 25 CBD oil to.

  • GlobeNewswire

    Emerald Health Therapeutics Commends Government of Ontario for Expanding Retail Cannabis Store Licences in Canada’s Largest Province

    OTCQX: EMHTF) commends the Government of Ontario for its newly announced plans to expand the province’s brick-and-mortar retail sales network for adult-use cannabis. Emerald believes that this initiative will position the industry and the Company for significant sales growth in Canada’s largest province. “After the first 25 stores began to open in Ontario, the industry saw overall sales of cannabis basically double,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald.

  • GlobeNewswire

    Emerald Health Therapeutics Joint Venture Launches Cannabis-Free Endocannabinoid-Supporting Health Supplement in Canada

    OTCQX: EMHTF), through its joint venture Emerald Health Naturals (“EHN”), has introduced a cannabis-free herbal and botanical endocannabinoid-supporting health supplement product line in Canada. EHN’s Endo products, which do not contain cannabis or its derivatives, aim to support the endocannabinoid system to help maintain equilibrium in the body and are already available in over 200 natural health food stores across Canada.

  • GlobeNewswire

    Emerald Health Therapeutics Receives Cultivation License for New-Build Organic Cannabis Operation in British Columbia

    OTCQX: EMHTF) has received its initial cultivation license from Health Canada for its new organic cannabis growing facility in Metro Vancouver, BC. Tailor-made for Emerald to produce high-quality organic cannabis, the operation comprises two 78,000 square foot greenhouses and 12 acres (~500,000 square feet) of outdoor cultivation, with potential for an additional 12 acres.

  • GlobeNewswire

    Emerald Health Therapeutics Applauds the Government of Canada for the Release of Final Ingestible Regulations

    OTCQX: EMHTF) is pleased that today the Government of Canada released the final regulatory framework for ingestibles and edibles. “The clarity of the final regulatory framework provides is important for Emerald in bringing our new product categories such as vape pens, ingestibles and edibles to market,” said Allan Rewak, VP Communications and Stakeholder Relations. The regulatory framework announced by Health Canada prohibits product forms that could be appealing to children and youth, combine alcohol or nicotine with cannabis and restrict production of infused cannabis products to dedicated licenced cannabis facilities approved by Health Canada.

  • GlobeNewswire

    Emerald Health Therapeutics to Present At Oppenheimer Consumer Growth and E-Commerce Conference

    OTCQX: EMHTF), a licensed producer of cannabis products for medical and recreational purposes, will participate in the Oppenheimer 19th Annual Consumer Growth and E-Commerce Conference on June 18, 2019 in Boston, MA. Bernie Hertel, Vice President of Finance and Communications, Emerald Health Sciences, will present a corporate overview and be available for 1x1 meetings.

  • GlobeNewswire

    Emerald Health Therapeutics Contracts for 1,200 Acres of Canadian Hemp Harvest, Reports Significant Progress on Factors Group Extraction Facility, and Forms US Hemp Subsidiary

    OTCQX: EMHTF) reports that is has expanded its agreement to purchase harvested hemp flower and leaf, or hemp chaff, from Emerald Health Hemp Inc. (“EHH”) from 1,000 to 1,200 acres for 2019. EHH is a wholly owned subsidiary of Emerald Health Sciences Inc. and a related party of Emerald. Based on last year’s harvest, Emerald expects production from the 1,200 acres to be at least 270,000 kg of hemp chaff in 2019 with, conservatively, approximately 2% cannabidiol (“CBD”) content.

  • GlobeNewswire

    Emerald Health Therapeutics to Participate at Investment and Industry Conferences in June

    VANCOUVER, British Columbia, June 03, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will participate in multiple upcoming investment and.

  • GlobeNewswire

    Emerald Health Therapeutics Reports First Quarter 2019 Financial Results; Demonstrates Continued Growth in Sales

    VANCOUVER, British Columbia, May 31, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today reported financial results for the quarter ended.

  • GlobeNewswire

    Emerald Completes Issuance of Shares in Lieu of Cash Due for Verdélite Acquisition

    OTCQX: EMHTF) today announced that the vendors (the "Vendors") of Verdélite Sciences, Inc. and Verdélite Property Holdings, Inc. (collectively, "Verdélite") have received 2,129,707 shares of Emerald (the "Shares") in lieu of $7.5 million of the $22.5 million they were to receive as the final payment for their shares of Verdélite. Each Share was valued at $3.5216, the five-day volume-weighted average price of the common shares of Emerald on the TSX Venture Exchange (the "TSXV"), discounted 10%, calculated as of April 30, 2019. The agreement to receive shares in lieu of cash was previously announced by the Company on May 1, 2019.

  • GlobeNewswire

    Emerald Health Therapeutics to Lead International Affairs Council on CBD and Hemp’s Dialog with FDA on CBD Product Policy as Part of the American Trade Association for Cannabis and Hemp

    OTCQX: EMHTF) has been appointed by the American Trade Association for Cannabis and Hemp (ATACH) to lead its International Affairs Council on CBD and Hemp in ATACH’s engagement with the US Food & Drug Administration (FDA) regarding policy pertaining to CBD-containing products and associated cross-border trade. The FDA is slated to begin public consultation on May 31 to discuss potential pathways for CBD products to come to market in the US.

  • GlobeNewswire

    Emerald Health Therapeutics Appoints Chief Operating Officer

    VICTORIA, British Columbia, May 22, 2019 -- Emerald Health Therapeutics, Inc. ("Emerald") (TSXV:EMH; OTCQX:EMHTF) has appointed Sean Rathbone as Chief Operating Officer. Mr..